S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.67 (+1.06%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.67 (+1.06%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.67 (+1.06%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
S&P 500   4,241.97 (+0.30%)
DOW   32,995.44 (-0.02%)
QQQ   358.67 (+1.06%)
AAPL   173.03 (+0.37%)
MSFT   318.22 (+1.54%)
META   304.80 (+1.28%)
GOOGL   134.91 (+1.87%)
AMZN   126.81 (+1.68%)
TSLA   257.95 (+4.63%)
NVDA   438.87 (+0.85%)
NIO   8.74 (+1.51%)
BABA   84.09 (-0.53%)
AMD   102.47 (+2.39%)
T   14.59 (-1.29%)
F   11.96 (-0.91%)
MU   67.94 (+0.16%)
CGC   0.75 (+9.07%)
GE   108.64 (+0.82%)
DIS   79.31 (-0.29%)
AMC   8.04 (+2.42%)
PFE   33.34 (-1.65%)
PYPL   58.08 (+1.36%)
NFLX   375.94 (-0.21%)
NASDAQ:VRNA

Verona Pharma (VRNA) Stock Forecast, Price & News

$15.32
-0.04 (-0.26%)
(As of 01:10 PM ET)
Compare
Today's Range
$15.11
$15.43
50-Day Range
$15.36
$22.09
52-Week Range
$9.26
$26.44
Volume
56,288 shs
Average Volume
459,345 shs
Market Capitalization
$9.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.60

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.8% Upside
$32.60 Price Target
Short Interest
Bearish
0.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Verona Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.46 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.86) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

842nd out of 966 stocks

Pharmaceutical Preparations Industry

394th out of 444 stocks


VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Price History

VRNA Stock News Headlines

Verona Pharma (NASDAQ:VRNA) Shares Gap Down to $16.94
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Analysts Set Verona Pharma plc (NASDAQ:VRNA) Target Price at $32.60
Verona Pharma (VRNA) Receives a Buy from H.C. Wainwright
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Verona Pharma: Targeting The Large COPD Market
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma Plc (NASDAQ: VRNA)
Wedbush Remains a Buy on Verona Pharma (VRNA)
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
VRNA - Verona Pharma plc
Verona Pharma (VRNA) Gets a Buy from H.C. Wainwright
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
8/03/2023
Today
10/04/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
35
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.60
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+112.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-68,700,000.00
Pretax Margin
-11,151.31%

Debt

Sales & Book Value

Annual Sales
$460,000.00
Price / Sales
21,225.85
Book Value
$3.05 per share

Miscellaneous

Free Float
610,879,000
Market Cap
$9.76 billion
Optionable
Not Optionable
Beta
0.27
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 58)
    Pres, CEO & Exec. Director
    Comp: $1.05M
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 60)
    Chief Financial Officer
    Comp: $784.38k
  • Dr. Kathleen A. RickardDr. Kathleen A. Rickard (Age 65)
    Chief Medical Officer
    Comp: $655k
  • Ms. Claire Louise Poll L.C.S.W. (Age 56)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Ms. Ostra Jewell
    Sr. VP of HR
  • Dr. Peter Spargo (Age 61)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 46)
    Ph.D., Sr. VP of R&D
  • Mr. Christopher Martin
    Sr. VP of Commercial













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2023?

5 brokerages have issued 12 month target prices for Verona Pharma's stock. Their VRNA share price forecasts range from $31.00 to $35.00. On average, they predict the company's share price to reach $32.60 in the next year. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2023?

Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA stock has decreased by 41.2% and is now trading at $15.36.
View the best growth stocks for 2023 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.16.

What ETF holds Verona Pharma's stock ?

ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $15.36.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $9.76 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -